ABT-737

For research use only. Not for use in humans.

目录号：S1002

CAS No. 852808-04-9

ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3144.65	现货
5mg	RMB 972.14	现货
50mg	RMB 4659.22	现货
100mg	RMB 7964.03	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的ABT-737发表文献322篇：

Science, 2021, 371(6535)eabc5386

PubMed: 33542149 ( click the link to review the publication )

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2022, 10.1021/acsami.1c22138

PubMed: 35014784 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):736

PubMed: 34312366 ( click the link to review the publication )

Cell Death Dis, 2021, 12(11):1011

PubMed: 34711816 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):784

PubMed: 34381022 ( click the link to review the publication )

J Infect, 2021, S0163-4453(21)00200-0

PubMed: 33892015 ( click the link to review the publication )

Antioxidants (Basel), 2021, 10(6)956

PubMed: 34203664 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5405

PubMed: 34065600 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

Commun Biol, 2021, 4(1):20

PubMed: 33398046 ( click the link to review the publication )

Blood Adv, 2021, 5(17):3497-3510

PubMed: 34432864 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Sci Adv, 2020, 6(47)eabc3465

PubMed: 33208362 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )
Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Development, 2020, 147(22)dev194555

PubMed: 33028610 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(7):1004-1017

PubMed: 32238439 ( click the link to review the publication )

Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )
Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Elife, 2019, 8e38730

PubMed: 31042147 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Biochem J, 2019, 476(9):1335-1357

PubMed: 30992316 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Life Sci, 2019, 232:116561

PubMed: 31247208 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )
J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6219-6233

PubMed: 31692812 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Cell Death Differ, 2018, 25(4):784-796

PubMed: 29229994 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(14):2663-2680

PubMed: 29396625 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Eur J Med Chem, 2018, 159:357-380

PubMed: 30308410 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )
Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15752

PubMed: 30361682 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Differ, 2017, 24(11):1963-1974

PubMed: 28777375 ( click the link to review the publication )

Elife, 2017, 6e22509

PubMed: 28425914 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )
Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(3)e00535-16

PubMed: 27821478 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

J Allergy Clin Immunol, 2017, 140(2):418-430

PubMed: 28043871 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2898

PubMed: 28661475 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Tumour Biol, 2017, 39(3):1010428317695965

PubMed: 28351336 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )
Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Cell Cycle, 2016, 15(12):1531-7

PubMed: 25483065 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )
Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35989-36001

PubMed: 27056884 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1989

PubMed: 26583329 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )
J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Chembiochem, 2015, 16(5):757-65

PubMed: 25711460 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Exp Hematol, 2015, 43(3):180-190.e6

PubMed: 25461257 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35667-83

PubMed: 26447615 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )
Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1514

PubMed: 25375379 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )
J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Cardiol, 2014, 176(3):923-9

PubMed: 25194861 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1532-45

PubMed: 23933817 ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e931

PubMed: 24263105 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )
Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Phys Biol, 2013, 10(3):035002

PubMed: 23735516 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )
Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )
Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

特性

ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

靶点

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放，促进BAX构象改变，BAX与凋亡相关。在白血病模型中，ABT-737按30 mg/kg处理，阻断53%白血病负荷，且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。^[1]通过使Mcl-1失活而使抵抗细胞（Hela和MCF-7）对ABT-737敏感。当Mcl-1无效时，ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。^[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。^[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖，并诱导细胞凋亡。最近研究显示，ABT-737作用于ATLL细胞，明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NYmzNWVJS2WubDDWbYFjcWyrdImgRZN{[Xl?	MV2yOVAhdk4EoB?=	M2DKflczKGh?	Ml21SG1UVw>?	MmfxZ4F2e2WmIEm3KUBtd3O\|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE>	M2XqWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkW3Nlg5Lz5{Nk[1O\|I5QDxxYU6=
KG1a	MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHzF[G4xNTFyIN88US=>	NYC3cZJwOjRiaB?=	M4\0OGROW09?	NXL6clJEUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NGDFTIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
Kasumi-1	NXvlOWFDS2WubDDWbYFjcWyrdImgRZN{[Xl?	M{n4OFAuOTBizszN	NFn5SmszPCCq	NGn2N4JFVVOR	Ml3KTWM2OD12Lki3JO69VSxiZHXjdoVie2W\|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NIfrZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
KG1a	M{C0eWFxd3C2b4Ppd{BCe3OjeR?=	MWWwMVExKM7:TR?=	MYqyOEBp	NEfZNXpFVVOR	NYnPXlBucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NYjEOZV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OVI4OTJpPkK2OVUzPzF{PD;hQi=>
Kasumi-1	MoTvRZBweHSxc3nzJGF{e2G7	MU[wMVExKM7:TR?=	NUP0TY5FOjRiaB?=	MYLEUXNQ	MW\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NUK3NVIoRjJ4NUWyO\|EzRC:jPh?=
MC-3	NXvzUIZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33sVVUwOTBxMkCg{txO	NULLc2NIOjRiaB?=	MXvEUXNQ	MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{[xOUc,OjZ2NEe2NVU9N2F-
HN22	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[zNk42NzdwNT:yNk42KM7:TR?=	M1LWd\|I1KGh?	M3LwRmROW09?	M17LeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NGi2TJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS0O\|YyPSd-Mk[0OFc3OTV:L3G+
MC-3	MlvmRZBweHSxc3nzJGF{e2G7	MWK1M\|ExNzJyIN88US=>	MV[yOEBp	MVnEUXNQ	MmCzbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	NULMZmVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OFc3OTVpPkK2OFQ4PjF3PD;hQi=>
HN22	NXW1bW1rSXCxcITvd4l{KEG\|c3H5	MnjKNk42NzdwNT:yNk42KM7:TR?=	M1nEdVI1KGh?	NVfib\|NWTE2VTx?=	NWe0UmhNcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{[xOUc,OjZ2NEe2NVU9N2F-
MOLT-4	M{\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHuWYY4OTBvNUCwNEBvVQ>?	NF\QNXM4OiCq	NH7ZelFFVVOR	MnOxTWM2OD1yLkG5PEDPxE1?	NUTHZlZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
RS4;11	NV6xWWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfVZ5BvOTBvNUCwNEBvVQ>?	MYK3NkBp	MXjEUXNQ	MXPJR\|UxRTBwMECyJO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
JURKAT	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTSNVAuPTByMDDuUS=>	MlK4O\|IhcA>?	M4fRVGROW09?	MlTmTWM2OD14NjFOwG0>	MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
CEM R	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInmRpkyOC13MECwJI5O	M2W5ZlczKGh?	MV7EUXNQ	MlGwTWM2OD13LkSg{txO	NWT0c4pHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM S	NVHIPHp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXENVAuPTByMDDuUS=>	NUTrd5V6PzJiaB?=	NHzKPFhFVVOR	NF[5UW5KSzVyPUGyMlEh\|ryP	NInucmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
MOLT-4	Ml36RZBweHSxc3nzJGF{e2G7	NGjHVWIyOC1zMECwJI5O	NV2wfFIzOjRiaB?=	NGX5RplFVVOR	M3XHWoNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
CEM S	M4e1XGFxd3C2b4Ppd{BCe3OjeR?=	NHLFS4EyOC1zMECwJI5O	MmG1NlQhcA>?	MXvEUXNQ	MkjLZ4F2e2W\|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG=	NHLiZXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
JURKAT	NXjNNY1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPiNVAxNTFyMECgcm0>	NGC0UW41QCCq	NEjBXY9FVVOR	Ml3MTWM2OD17NUZCtVkvOyCwTR?=	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzN{KyOlkoRjJ4MUeyNlY6RC:jPh?=
LOUCY	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGxNFAuOTByMDDuUS=>	NEDUUnk1QCCq	MW\EUXNQ	MWTJR\|UxRTN{LklCtVExNjlibl2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF5MkK2PUc,OjZzN{KyOlk9N2F-
WM-115	M3fJemNmdGxiVnnhZoltcXS7IFHzd4F6	M3fBSVExOMLibl2=	NF\pPZc4OiCq		M3m3bIVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[3O\|YoRjJ4MUG2O\|c3RC:jPh?=
B16	MlHlR4VtdCCYaXHibYxqfHliQYPzZZk>	MVGxNFDDqG6P	MVu3NkBp		MYflcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	NXfyTYpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVY4PzZpPkK2NVE3Pzd4PD;hQi=>
HL-60	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NE\hTo44OiCq		MULJR\|UxyqB;IEGwMlchdk1?	MoXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEW2NFkoRjJ4MES1OlA6RC:jPh?=
MOLM-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHhSWtUPzJiaB?=		MWPJR\|UxyqB;IEK3Mlkhdk1?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
OCI-AML3	NFvoTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17NN\|czKGh?		NVHSWnJZUUN3MNMgQUAyQTVyIH7N	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
BCWM.1	NVLv[IgxSXCxcITvd4l{KEG\|c3H5	MXGwMVEvPiEQvF2=	NVLlVVdHOjRiaB?=		NUfTR3licW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh7M{K5NEc,OjV6OUOyPVA9N2F-
MWCL-1	Mli3RZBweHSxc3nzJGF{e2G7	NH;pPXIxNTFwNjFOwG0>	MXWyOEBp		MoDRbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M{TYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEmzNlkxLz5{NUi5N\|I6ODxxYU6=
MM.1s	NHrheVNCeG:ydH;zbZMhSXO\|YYm=	NIjaTWoxNTFwNjFOwG0>	NXnQeYVjOjRiaB?=		NFzvU4ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NWTycIxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PVMzQTBpPkK1PFk{OjlyPD;hQi=>
HCT116	MVfGeY5kfGmxbjDBd5NigQ>?	M2rqZVMwOTBizszN	NWTZSWlOOTMEoHlCpC=>	MYXEUXNQ	MV\pcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	NFHXXlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116 BAX BAK1 DKO	M4[3XWZ2dmO2aX;uJGF{e2G7	NWSzZpN{Oy9zMDFOwG0>	MYOxNuKhcMLi	NWDUe45vTE2VTx?=	MnHtbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w	NYDjbG1NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVUxOjhpPkK1O\|E2ODJ6PD;hQi=>
HCT116	M{D0SGZ2dmO2aX;uJGF{e2G7	NFfBOYEyOCEQvF2=	MXSxNuKhcMLi	MX;EUXNQ	NILjOXZqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th	NEfndIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116 BAX BAK1 DKO	NX3RV2M4TnWwY4Tpc44hSXO\|YYm=	MlP1NVAh\|ryP	M3vF[FEzyqCqwrC=	M1;WT2ROW09?	MVvpcoNz\WG\|ZYOgS2ZRNUyFM1KgdJVv[3Sj	Mn7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116	MlLQRZV1d3CqYXf5JGF{e2G7	MormNVAh\|ryP	MYCxNuKhcMLi	NUPOZVB7TE2VTx?=	NVnofIxRcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	NYfaU2JqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVUxOjhpPkK1O\|E2ODJ6PD;hQi=>
HCT116 BAX BAK1 DKO	MYfBeZRweGijZ4mgRZN{[Xl?	NETzcXkyOCEQvF2=	NFTHcYYyOsLiaNMg	NVHMUYpOTE2VTx?=	MX\pcoR2[2W\|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=>	M4HDTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G1NFI5Lz5{NUexOVAzQDxxYU6=
U937	NFmxcFRCeG:ydH;zbZMhSXO\|YYm=	M1jOZlAvOTJ3LUKg{txO	MXSyOEBp		MUXlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?=	M4DvelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G0NFI1Lz5{NUexOFAzPDxxYU6=
U937	Mn;5RZBweHSxc3nzJGF{e2G7	M3LPelAvPSEQvF2=	MlztNlQhcA>?		MV;lcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNECyOEc,OjV5MUSwNlQ9N2F-
HL-60 AAA-Bcl-2	M2PjeWFxd3C2b4Ppd{BCe3OjeR?=	NYXwR3NKOC13IN88US=>	M{P1VFQ5KGh?		NUniPFU1UUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXKxfZFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVE1PjBpPkK1O\|EyPDZyPD;hQi=>
HL-60 EEE-Bcl-2	MkO0RZBweHSxc3nzJGF{e2G7	MUmwMVUh\|ryP	NFjOWHg1QCCq		Mk\OTWM2OD13IN88cg+9lCCrbnT1Z4V{KGOnbHygZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYH2UYpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVE1PjBpPkK1O\|EyPDZyPD;hQi=>
U87	M4fJSGZ2dmO2aX;uJGF{e2G7	MUe1NEDPxE1?	M4jCd\|I1KGh?		NYTveIFVemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=>	M3jZd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[3OlY{Lz5{NU[2O\|Y3OzxxYU6=
K562	NXPjNI1iS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkjKNU0yOCEQvF2=	M3XPbFQ5KGh?	MYrEUXNQ	M1vSTWlEPTB;Mk[uO{DPxE1?	NIHsbXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5OlU3OSd-MkW1PVY2PjF:L3G+
K562/Mcl -1-IRESBim	M3jxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz2TWM2OD17LkOg{txO	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
K562/Bcl- 2-IRESBim	MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHrTWM2OD1yLkO1JO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
Jurkat	NFjadlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPTTWM2OD1yLk[2JO69VQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
JurkatΔBak	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\TO5BXUUN3ME61NEDPxE1?	NXXrSWtTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
HL60/VCR	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPyS2pEUUN3ME6xNFAh\|ryP	M2HIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
Kasumi-1	NWHDRVYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMEGg{txO	NHW2fWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
Kasumi-1/ABT	NIPmfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwNUGg{txO	Ml7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
THP-1	M1X4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwMkeg{txO	NILEUIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
U937	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrleWVKSzVyPUWuNlkh\|ryP	NFXQbGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
C1498	M1PxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnXTWM2OD14LkGzJO69VQ>?	MlrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
RPMI 8226	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV32WnNOUUN3ME2wMlI2KM7:TR?=	NXHab21ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
MM.1S	NYn4NoZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLNU2pOUUN3ME2wMlQxKM7:TR?=	NYPjcGZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
NCI-H929	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\OfJpOUUN3ME2xOU4zOSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
U266	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS2dWJ6UUN3ME2wMlY5KM7:TR?=	M3LNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
MCF-7	NFr0WXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3HufVUh\|ryP	NWrz[otWPDhiaB?=	NXXMZmtTTE2VTx?=	MVflcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v	NVvPSm5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
MCF-7	NXjkd41QSXCxcITvd4l{KEG\|c3H5	MVq1JO69VQ>?	NXKwTHpbPC9{ND:0PEBp	M{nXVGROW09?	NXjjbXJPcW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA>	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MCF-7	Mk\uSpVv[3Srb36gRZN{[Xl?	NUHQUZllPSEQvF2=	NGTURmMzPCCq	MVfEUXNQ	MWjlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
MDA-MB 231	NFfm[YtHfW6ldHnvckBCe3OjeR?=	MVW1JO69VQ>?	NYn3cHpmOjRiaB?=	Mmj0SG1UVw>?	M3WwOIVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	NWWzfXF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
ZR-75-1	NHr3cotHfW6ldHnvckBCe3OjeR?=	M{HzOFUh\|ryP	NYqyPINTOjRiaB?=	MUTEUXNQ	MUnlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
A549	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Ml76NE0zOCEQvF2=	NGX5OFc4OiCq	M4fzT2ROW09?	MXXk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	M4S0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
H1299	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M{\WSlAuOjBizszN	MofCO\|IhcA>?	MYTEUXNQ	M3;wb4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
HO-8910	MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWKwMVIxKM7:TR?=	NEHo[JI4OiCq	NXS0Xm5ZTE2VTx?=	MWHk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NXnlSFZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
HT-29	MlTrR4VtdCCYaXHibYxqfHliQYPzZZk>	M{K0XVAuOjBizszN	M1q5UVczKGh?	NFW2XJhFVVOR	MUjk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NYPBPXVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
HCT-116	M3r1UGNmdGxiVnnhZoltcXS7IFHzd4F6	NUXURZhsOC1{MDFOwG0>	MmPFO\|IhcA>?	MVLEUXNQ	MkLw[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	M1v4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
A549	MoLWRZBweHSxc3nzJGF{e2G7	MW[yNEDPxE1?	NVOwWJhWPDhiaB?=	MY\EUXNQ	MkG3bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	NH;hblM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
H1299	NWjOZVNbSXCxcITvd4l{KEG\|c3H5	MkTjNlAh\|ryP	NUjaSpFKPDhiaB?=	Mm\GSG1UVw>?	MoLSbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	NVHDSYVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
Sc-1	M1zoRmNmdGxiVnnhZoltcXS7IFHzd4F6	M1LrZVAvODByMT2xJO69VQ>?	MXu5OkBp		NVrHPGwz\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{O1NFgoRjJ3M{ezOVA5RC:jPh?=
OcI-LY18	M2LVV2NmdGxiVnnhZoltcXS7IFHzd4F6	MWOwMlAxODFvMTFOwG0>	NIm2cYg6PiCq		M3vaV4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NXHjZVBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|M2ODhpPkK1N\|c{PTB6PD;hQi=>
RL	MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NH\xN\|YxNjByMEGtNUDPxE1?	M2\rS\|k3KGh?		M3TFdIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5M{WwPEc,OjV\|N{O1NFg9N2F-
RKO	M1fi[GNmdGxiVnnhZoltcXS7IFHzd4F6	MWGwMVExKM7:TR?=	MX:yOQKBkWkEoB?=	NEjwSFRFVVOR	Mn7iTWM2OD8kgJmyOgKBkcL3TR?=	MoWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
Caco-2	MmfUR4VtdCCYaXHibYxqfHliQYPzZZk>	MnXtNE0yOCEQvF2=	MojxNlTjiImqwrC=	M{jnRmROW09?	MnP5TWM2OD1zOT635qCKyrWP	M3PGclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C0N\|g{Lz5{NUOwOFM5OzxxYU6=
DLD1	NHjrZ3RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M{TKW\|AuOTBizszN	MoXINlTjiImqwrC=	MoDqSG1UVw>?	NYjxSJZ1UUN3ME2xPE44QOLCidM1US=>	NWLQOHdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFQ{QDNpPkK1N\|A1Ozh\|PD;hQi=>
LS411N	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NEXxN4cxNTFyIN88US=>	MWWyOQKBkWkEoB?=	M2\jcmROW09?	MWfJR\|UxRTFzLkS35qCKyrWP	M1G4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C0N\|g{Lz5{NUOwOFM5OzxxYU6=
SW620	NXv5XG5{S2WubDDWbYFjcWyrdImgRZN{[Xl?	NELPXoYxNTFyIN88US=>	MknGNlTjiImqwrC=	NY\uboVqTE2VTx?=	NE[yTYpKSzVyPUGyMlI16oDLwsXN	NFPGNFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOFM5Oyd-MkWzNFQ{QDN:L3G+
HCT116	M2LpXmNmdGxiVnnhZoltcXS7IFHzd4F6	MXGwMVExKM7:TR?=	NXPKXIhWOjUkgJnoxsA>	NFXHXVZFVVOR	NYLOUppJUUN3ME2yNE41QeLCidM1US=>	Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
HaCaT	M{XMNWNmdGxiVnnhZoltcXS7IFHzd4F6	MVKwMlEwOS9zMDFOwG0>	M17GNFI1KGh?	NWewVFJpTE2VTx?=	NV\uSW5i\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVjKTFVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
A5-RT3	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1HXcFAvOS9zL{GwJO69VQ>?	M4fsRVI1KGh?	M3fmemROW09?	Mnnr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M{Hj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
HaCaT	NESyd3RHfW6ldHnvckBCe3OjeR?=	MVSxNQKBkc7:TR?=	NHnBVGszPC92ODDo	NX3UeYxLTE2VTx?=	MlXhbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w	M2LFRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	MXLGeY5kfGmxbjDBd5NigQ>?	NY\QfVdMOTEkgJpOwG0>	M17CRVI1NzR6IHi=	NEfOOmRFVVOR	NUTRd4d2cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	Mlq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVUoRjJ3MkGwO\|k2RC:jPh?=
A5-RT3	MVzGeY5kfGmxbjDBd5NigQ>?	NVfyUIFOPSEQvF2=	M1XNfVYhcA>?	NFnDfnFFVVOR	MnT0bY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=>	NV;B[mlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
U266	NUjNUndRTnWwY4Tpc44hSXO\|YYm=	MmnCOVAxNzd3MDDuUS=>	MnfoNlQwPDhiaB?=	NU\3c3pWTE2VTx?=	NGrwRYVld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFgoRjJ3MkC4PFg5RC:jPh?=
RPMI8226	MXnGeY5kfGmxbjDBd5NigQ>?	NG\nRoc2ODBxN{WwJI5O	NWXUWXIyOjRxNEigbC=>	NXnB[GVvTE2VTx?=	MkPB[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFgoRjJ3MkC4PFg5RC:jPh?=
MM.1S	NXS1SXAxTnWwY4Tpc44hSXO\|YYm=	MmnmOVAxNzd3MDDuUS=>	M3\2b\|I1NzR6IHi=	NIr1XZRFVVOR	NYPFO\|N6\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	M4e0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFg5Lz5{NUKwPFg5QDxxYU6=
Clone A	NWnaWpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPjfmRLOC5{4pETOlAh\|ryP	M1\tOFczKGh?	NEjCOXRFVVOR	Mle3TWM2OD15LkWg{txO	M{TZV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
CX-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjyTph5OC5{4pETOlAh\|ryP	M{XafVczKGh?	MnjkSG1UVw>?	M1faU2lEPTB;MT64JO69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyOEi4Nkc,OjV{MEi4PFI9N2F-
LS174T	M1LMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKzRVA3OC5{4pETOlAh\|ryP	MXi3NkBp	NHTaUY5FVVOR	NYLmUWc6UUN3ME2xPE4{KM7:TR?=	Mli2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFIoRjJ3MkC4PFgzRC:jPh?=
HT29	NEnjfJZCeG:ydH;zbZMhSXO\|YYm=	Mmn5NU82NzFyIN88US=>	MoC5OFghcA>?		MXnjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUKxPFgoRjJ3MUmyNVg5RC:jPh?=
SW480	MkHXRZBweHSxc3nzJGF{e2G7	M1jkUlEwPS9zMDFOwG0>	M4roU\|Q5KGh?		MYjjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2jqd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUmyNVg5Lz5{NUG5NlE5QDxxYU6=
Colo205	NFrMVYFCeG:ydH;zbZMhSXO\|YYm=	MmjWNU82NzFyIN88US=>	MoPUOFghcA>?		NIDVdJVk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUKxPFgoRjJ3MUmyNVg5RC:jPh?=
Caco2	MWXBdI9xfG:\|aYOgRZN{[Xl?	M2nKclEwPS9zMDFOwG0>	M3rhUFQ5KGh?		M2rYbYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGKwOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5NlE5QCd-MkWxPVIyQDh:L3G+
PCI-13	M3\5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYm3NkBp	NUPFdGpuTE2VTx?=	NFHLSJlIUTVyPUG1JOKyKDFwODFOwG0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
PCI-15B	NIOwRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFPMRm84OiCq	NHPXVWpFVVOR	MmTZS2k2OD1zMTFCtUA1NjVizszN	MofHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPFcoRjJ3MUO5N\|g4RC:jPh?=
UM-SCC22B	NGKz[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGC5Wpg4OiCq	MlX4SG1UVw>?	NELwc4hIUTVyPUG5JOKyKDJwOTFOwG0>	NGmxe4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
UM-SCC47	NFLhPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUC3NkBp	NUDyVlk5TE2VTx?=	MVjHTVUxRTF7INMxJFEzNjNizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
93-VU-147T	NFi0[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEnaOGg4OiCq	M1PYPWROW09?	NITvVZNIUTVyPUSuN{DDuSB\|LkWg{txO	MnHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPFcoRjJ3MUO5N\|g4RC:jPh?=
UD-SCC2	M3[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVy3NkBp	NF7n[FNFVVOR	MoPRS2k2OD1{ODFCtUAzNjlizszN	NGfGfI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
UPCI:SCC90	NVzGXXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWm3NkBp	NVPGTG1PTE2VTx?=	MWXHTVUxRTZwNjFCtUAyNjVizszN	NF;LOmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
RPMI-8226	MojQR4VtdCCYaXHibYxqfHliQYPzZZk>	NEjLNXQyOjVxMkWwM\|UxOCCwTR?=	MXm0PIjDqA>?	MVvEUXNQ	NEK1T\|Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
OPM-2	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mkm1NVI2NzJ3MD:1NFAhdk1?	NFzEfow1QGkEoB?=	NH\QZphFVVOR	NGf1W5Rl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
RPMI-8226	MUHBdI9xfG:\|aYOgRZN{[Xl?	MVqxNlUwOjVyL{WwNEBvVQ>?	MorTOFhpyqB?	M1zMR2ROW09?	M3Pqdolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEiyNFIoRjJ3MEC4NlAzRC:jPh?=
OPM-2	NF7Xd4JCeG:ydH;zbZMhSXO\|YYm=	NXjBZYhqOTJ3L{K1NE82ODBibl2=	M3XvXVQ5cMLi	NHTTfI1FVVOR	NUPjWIRzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{\1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4NlAzLz5{NUCwPFIxOjxxYU6=
COG-LL-319	NEDHSIRHfW6ldHnvckBCe3OjeR?=	NF[1R\|EyODBibl2=	M4fDW\|EwOy94IHi=	MVPEUXNQ	MVjpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	NWnkPZRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVE1PzJpPkK0PVUyPDd{PD;hQi=>
RS4;11	M3n1PWZ2dmO2aX;uJGF{e2G7	M1e5UFExOCCwTR?=	NUnzZ5IyOS9\|L{[gbC=>	NVzsUpkzTE2VTx?=	M3XVNYlv\HWlZYOgZ4F{eGG\|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V?	NWHHeVN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVE1PzJpPkK0PVUyPDd{PD;hQi=>
FL5.12	M3rnS2Z2dmO2aX;uJIF{e2G7				NVHKOVRXWmW4ZYLzZYwhd2ZiY4n0c4tqdmVid3n0bIRz[XejbDDwdo91\WO2aX;uJIlvKEmOMzDk[ZBmdmSnboSgRoNtOiCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gZo93cW6nIHflcIF1cW5uIFXDOVAhRSByLkCwPEDPxE1w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
DoHH2	M1ryWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M{XCR2lvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gSI9JUDJiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kA{LSCIQmOsJGVEPTBiPTCwMlAxQDNizszNMi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
RS11380	Mn;VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M3TmSWlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gVnMyOTN6MDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDNnIF\CV{whTUN3MDC9JFAvODF2IN88UU4>	NF7l[pc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	MULGeY5kfGmxbjDhd5NigQ>?				M13zdHJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcE15VCCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gZo93cW6nIHflcIF1cW5uIFXDOVAhRSByLkCzJO69VS5?	NGD1TFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	M3fteWZ2dmO2aX;uJIF{e2G7				MYLS[ZZmenOjbDDv[kBkgXSxa3nu[UB4cXSqZILhe4FtKHC{b4TlZ5Rqd25iaX6gTWw{KGSncHXu[IVvfCCEY3yyJI93\XKneIDy[ZN{cW6pIH3veZNmKE[ONT6xNkBk\WyuczDpckBxemW\|ZX7j[UBw\iB\|JTDGRnMtKEWFNUCgQUAxNjB3IN88UU4>	NITPd5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	M{\UUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MXzJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuJIh2dWGwIFTvTGgzKGOnbHzzJI93\XKneIDy[ZN{cW6pIFLjcFIhcW5icILld4Vv[2Vib3[gNVAmKEiVLDDFR\|UxKD1iMD6xN{DPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
RS11380	MkHUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MmrVTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpckBpfW2jbjDSV\|EyOzhyIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOTBnIFjTMEBGSzVyIE2gNE4yPSEQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
SUDHL4	NFK1ZYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1rxfGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gV3VFUEx2IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOyViRlLTMEBGSzVyIE2gNE4zOiEQvF2u	M4DSTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
FL5.12	M2HDeWZ2dmO2aX;uJIF{e2G7				MoTYVoV3\XK\|YXygc4Yh[3m2b3vpcoUhf2m2aHTyZZdidCCycn;0[YN1cW:wIHnuJGlNOyCmZYDlcoRmdnRiQnPsMZhNKG:4ZYLlfJBz\XO\|aX7nJI1wfXOnIF\MOU4yOiClZXzsd{BqdiCycnXz[Y5k\SCxZjCzKUBHSlNuIFXDOVAhRSByLkKyJO69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
SUDHL4	NHH4SplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NXnlR4drUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBUXUSKTESgZ4VtdHNib4\ldoV5eHKnc4PpcochSmOuMjDpckBxemW\|ZX7j[UBw\iBzMDWgTHMtKEWFNUCgQUAxNjh3IN88UU4>	NXrTT21mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
FL5.12	M4juNmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlmyNlQhcHK\|		Mo[4R5l1d3SxeHnjbZR6KGGpYXnud5QhUUx\|LXTldIVv\GWwdDDtc5V{\SCITEWuNVIh[2WubIOgc5ZmemW6cILld5NqdmdiaIXtZY4hSmOuMjDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7IHnuJIFje2WwY3Wgc4Yhe2W{dX2sJGVEPTBiPTCwMlAxPzdizszNMi=>	NHXmNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEi0NVg5Oid-MUi4OFE5QDJ:L3G+
FL5.12	NEfwfGNEgXSxdH;4bYNqfHliYYPzZZk>		MmXnNlQhcHK\|		NEm3e4pEgXSxdH;4bYNqfHliYXfhbY5{fCCLTEOt[IVx\W6mZX70JI1wfXOnIF\MOU4yOiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDoeY1idiCEY3ytXGwh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgNlQhcHK\|IHL5JG1VWyCjc4PhfUBqdiCjYoPlcoNmKG:oIIPldpVuNCCHQ{WwJF0hOC5yMzFOwG0v	M3jpUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
NCI-H146	Mkn1R5l1d3SxeHnjbZR6KGG\|c3H5		MmnBOFghcHK\|		NVvQZotwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixOFYh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGmwIIDy[ZNmdmOnIH;mJFExLSCqdX3hckB{\XK3bTygSWM2OCB;IECuNFg4KM7:TT6=	M{fjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
CLL	MmPxRZBweHSxc3nzJIF{e2G7				MlzkTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCFTFygZ4VtdHNuIFXDOVAhRSByLkCwOFUh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl{NUSzN{c,OjB7MkW0N\|M9N2F-
MEF	NFLud49EgXSxdH;4bYNqfHliYYPzZZk>		NF3UO5MzPCCqcoO=		NU\Yc2R3S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNUUhe2W{dX2sJGVEPTBiPTCwMlAxOjB\|IN88UU4>	M17rWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{[2Nlk2Lz5{MUO2OlI6PTxxYU6=
MEF	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		NWDqXnllOjRiaILz		M4nW[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJI1kdC1zIHTl[olkcWWwdDDNSWYh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IFPlcIwhfGm2ZYKg[4xwKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGwKUB{\XK3bTygSWM2OCB;IECuNFUyKM7:TT6=	NIjidpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	NEn5PWpEgXSxdH;4bYNqfHliYYPzZZk>		NHLldFYzPCCqcoO=		MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDtZ4wuOSCmZX\pZ4lmdnRiTVXGJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCFZXzsJJRqfGW{IHfsc{Bie3OjeTDpckBxemW\|ZX7j[UBw\iBzMDWg[oV1[WxiYn;2bY5mKHOncoXtMEBGSzVyIE2gNE4xPTFizszNMi=>	M1f2UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{[2Nlk2Lz5{MUO2OlI6PTxxYU6=
RS4:11	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NVX5ZVEySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSV\|Q7OTFiY3XscJMhcW5icILld4Vv[2Vib3[gNVAmKGi3bXHuJJNmenWvLDDFR\|UxKD1iMD6wNlQh\|ryPLh?=	M{Dqd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUK2NlQ4Lz5{OEmyOlI1PzxxYU6=
MOLT4	M13MW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7				MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHnuJJBz\XOnbnPlJI9nKDFyJTDoeY1idiC\|ZYL1cUwhTUN3MDC9JFAvPjJ{IN88UU4>	MnnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFcoRjJ6OUK2NlQ4RC:jPh?=
Jurkat	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		MoK4OFghcHK\|		NWm1OWFZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUnW{a3H0JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTCxMlM5KM7:TT6=	M4DVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{SzPFU5Lz5zOUe0N\|g2QDxxYU6=
HCT116	NW\nfnV4S3m2b4TvfIlkcXS7IHHzd4F6		NGrxelI1QCCqcoO=		NXn5W5lbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTC0MlA3KM7:TT6=	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
SU-8686	Mli5R5l1d3SxeHnjbZR6KGG\|c3H5		M{TjOVQ5KGi{cx?=		NXHxNlJ2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1VvOE[4OkBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG\|c3H5MEBKSzVyIE2gOE4zPCEQvF2u	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
H460	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		M2LTdVQ5KGi{cx?=		MkDUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hQC5yMzFOwG0v	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
Hepa-1c1c7	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		NXXpWnF2PDhiaILz		M{ThR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGhmeGFvMXOxZ\|ch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhUUN3MDC9JFgvPjhizszNMi=>	NXXofW0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
MCF7	M{jBTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYm0PEBpenN?		MnHHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hOjFwMk[g{txONg>?	NG\ZTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0N\|g2QCd-MUm3OFM5PTh:L3G+
DU145	MmG0R5l1d3SxeHnjbZR6KGG\|c3H5		MUe0PEBpenN?		M1m4N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB{Nz62JO69VS5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
HCT116	NXSxSFdJS3m2b4TvfIlkcXS7IHHzd4F6		NFTMcmk4OiCqcoO=		NIfQfVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiZYjwdoV{e2mwZzDCZ4wugExuIFLjcE0zKGGwZDDNZ4wuOSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPDdwNzFOwG0v	MmjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzN{K3NFEoRjJ{MUeyO\|AyRC:jPh?=
BL21 (DE3)	MnfMSpVv[3Srb36gZZN{[Xl?		M1fs[\|IhcHK\|		MnP3Rolv\GmwZzDh[oZqdmm2eTD0c{BPNXSncn3pcpV{KD[[IFjpd{11[WepZXSgbJVu[W5iQnPsNkBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkCwNkDPxE1w	M2rlU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
BL21 (DE3)	MUPGeY5kfGmxbjDhd5NigQ>?		M2XlNVIhcHK\|		NX3X[GxxSmmwZHnu[{Bi\m[rbnn0fUB1dyCQLYTldo1qdnW\|IEjYJGhqey22YXfn[YQhcHWvYX6gRoNtNXiOIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3MDC9JFAvODB4IN88UU4>	NFTw[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS0PFk5QCd-MkK0OFg6QDh:L3G+
NCI-H146	M1nCTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{DxW\|Qh\GG7cx?=		NGrmfYZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG0OkBk\WyuczDh[pRmeiB2IHThfZMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk4KM7:TT6=	M4iyWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
NCI-H1417	MmPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVPpNpJVPCCmYYnz		NVzocJpVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOFE4KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4yOyEQvF2u	M4rZPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
CCRF-CEM	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		NXy4NYpmPDhiaILz		M{X0O2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSClZXzseIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MkjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OEK5PVEoRjJ{NUiyPVkyRC:jPh?=
HL60	MljmR5l1d3SxeHnjbZR6KGG\|c3H5		MkDZOFghcHK\|		NFXDTYJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV6Mkm5NUc,OjJ3OEK5PVE9N2F-
K562	MnXXR5l1d3SxeHnjbZR6KGG\|c3H5		NWr3WHhpPDhiaILz		NXnn[5VzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB\|ND63JO69VS5?	M4nlblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUiyPVkyLz5{MkW4Nlk6OTxxYU6=
NCI-H146	Ml;BRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWj3fJdPPCCmYYnz		MkPURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE1PiClZXzsd{Bi\nSncjC0JIRigXNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODN5IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
NCI-H1963	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmOzOEBl[Xm\|		NXvKVpBiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7NkOgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkC1PUDPxE1w	NG\YSFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
NCI-H1417	M3HKT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1K5TVQh\GG7cx?=		NH3qWG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTRzNzDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWODDhd5NigSxiSVO1NEA:KDBwNEGyJO69VS5?	Moj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NEe1PVgoRjJ{N{S3OVk5RC:jPh?=
RS4:11	MojTRZBweHSxc3nzJIF{e2G7		M4HCOFQ5KGi{cx?=		M1fuPGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gRoNtOiCmZYDlcoRmdnRiaIXtZY4hWlN2OkGxJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comsJGlEPTBiPTCwMlI4KM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzNEC1OEc,OjN\|MUSwOVQ9N2F-
K562	NY\IcIR6SXCxcITvd4l{KGG\|c3H5		NES3bWw1QCCqcoO=		NVzCWJZVUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBO[2xzIHTldIVv\GWwdDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comsJGlEPTBiPTCxOk41KM7:TT6=	MoDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUSwOVQoRjJ\|M{G0NFU1RC:jPh?=
NCI-H1963	NUPiPXdPS3m2b4TvfIlkcXS7IHHzd4F6		NVP3d5J1PCCmYYnz		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7NkOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IGfTWEBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6=	NIjnSWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H187	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		M2q1SFQh\GG7cx?=		NYHoXoJHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPFch[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOEBl[Xm\|IHL5JHdUXCCjc4PhfUwhUUN3MDC9JFAvOTN5NzFOwG0v	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H1417	NHPQTlNEgXSxdH;4bYNqfHliYYPzZZk>		MX60JIRigXN?		M3\UNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUSxO{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0JIRigXNiYomgW3NVKGG\|c3H5MEBKSzVyIE2gNE4yPzN2IN88UU4>	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
HL60	NUDmUollT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXvxe2E{PzJiaILz		MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlk4KM7:TT6=	M4jUTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
MCF7	NVjibVd{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mlz5O\|IhcHK\|		NUjCTVl3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjVwM{Og{txONg>?	NFPPNGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exNlk{QSd-Mke3NVI6Ozl:L3G+
U266	M1jkR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2rhU\|czKGi{cx?=		Ml\YS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWVI3PiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNlcvOzVizszNMi=>	M3y5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
SKOV3	MnjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUO3NkBpenN?		MlK0S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ3NjV7IN88UU4>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzMkmzPUc,Ojd5MUK5N\|k9N2F-
RS4:11	NVvEOnF2S3m2b4TvfIlkcXS7IHHzd4F6		NWLnW2RQOjRiaILz		Ml7qR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnM1QjFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zN{DPxE1w	M{O4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEWzNVM2Lz5{OUS1N\|E{PTxxYU6=
Remb1	M{XQdmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NVHh[5loOjRiaILz		M1LuPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJmdWJzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT60JO69VS5?	NInMcXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1N\|E{PSd-Mkm0OVMyOzV:L3G+
BL21	MVHGeY5kfGmxbjDhd5NigQ>?	NHXtTlIyOCC3TR?=	NV\wRolHOyCqcoO=		NXe5dFBKTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBIOTl4QTDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMECxJO69VS5?	NVLTWmhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	Mm\OSpVv[3Srb36gZZN{[Xl?	M3HURVExKHWP	NIS1bY4{KGi{cx?=		NXHmXlh2TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBCQTOYIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMEG0JO69VS5?	NWTsTVZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	M{LtV2Z2dmO2aX;uJIF{e2G7	M4G2flExKHWP	NGq5T2U{KGi{cx?=		M1zROWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgXVE6PUZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByMUWg{txONg>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	MYjGeY5kfGmxbjDhd5NigQ>?	NHr2NI8yOCC3TR?=	M4PRVFMhcHK\|		NEDzSIVFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIGfpcIQhfHmyZTDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xODN2IN88UU4>	M{\vTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NEjwNoRHfW6ldHnvckBie3OjeR?=	Ml;4NVAhfU1?	NVS0[XRLOyCqcoO=		NV\ySYg2TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGOTJ7SDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEC0OUDPxE1w	NXK4fJlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NHm5UWZHfW6ldHnvckBie3OjeR?=	M2ftTlExKHWP	M2j5U\|MhcHK\|		NYj5UZV6TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGQT[JIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMEW4JO69VS5?	M1zYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NEnDOZBHfW6ldHnvckBie3OjeR?=	MWixNEB2VQ>?	MmPzN{BpenN?		MkXHSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDBNVQzT2SnbIThNVM3XCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODFizszNMi=>	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	M3vyXmZ2dmO2aX;uJIF{e2G7	MnrVNVAhfU1?	MYGzJIhzew>?		M2Dp[2Rqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgRVE1OkdibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjB{MTFOwG0v	M{PMOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NHu1cJhHfW6ldHnvckBie3OjeR?=	NXfHOXIyOTBidV2=	Mk\5N{BpenN?		M3SycGRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgUFE{OFZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjB3ODFOwG0v	M3\LVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	M4nHNmZ2dmO2aX;uJIF{e2G7	M2G3O\|ExKHWP	NVrwN21tOyCqcoO=		M2\HTWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGg[IVtfGFzM{\UJI12fGGwdDDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIHPlcIx{KGG2IEGwJJVOKGGodHXyJFMhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZ49ueGW2aYTpc44h[XO\|YYmsJGtqKD1iMD6wOkDPxE1w	NVHrNmoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NXmzcVdkTnWwY4Tpc44h[XO\|YYm=	Mn76NVAhfU1?	M4DIe\|MhcHK\|		NXiyN3h1TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBNOTNyQTDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEezJO69VS5?	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NVjZNJZjTnWwY4Tpc44h[XO\|YYm=	M2P0W\|ExKHWP	M17FZ\|MhcHK\|		NW\TbG9bTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBTOTByRTDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMU[g{txONg>?	NIX5TGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	M3zoTGZ2dmO2aX;uJIF{e2G7	MlT0NVAhfU1?	NWnLNlQ1OyCqcoO=		MV7EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIG[xOFFCKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4yQSEQvF2u	MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NIPzUW1HfW6ldHnvckBie3OjeR?=	NXrxVlFFOTBidV2=	NHL5c\|A{KGi{cx?=		NWP5XIh4TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBCOTR{VDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMkeg{txONg>?	NEK0bW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	M{HQbmZ2dmO2aX;uJIF{e2G7	M{jR[FExKHWP	NIixe4o{KGi{cx?=		MUHEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFyxN\|BIKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4zQSEQvF2u	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	NX3CXoIxTnWwY4Tpc44h[XO\|YYm=	MYWxNEB2VQ>?	NW\DbGJlOyCqcoO=		M4HxbmRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgSlk4XiCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOyEQvF2u	MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	M4j6TGZ2dmO2aX;uJIF{e2G7	NX61U5lDOTBidV2=	NXT4PVE6OyCqcoO=		MmThSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVAyUCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOzhizszNMi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21 (DE3)	NWDzcppVTnWwY4Tpc44h[XO\|YYm=		M4G2VVIhcHK\|		MnvJRolv\GmwZzDh[oZqdmm2eTD0c{BPNXSncn3pcpV{KD[[IFjpd{11[WepZXSgbJVu[W5iQnPsNkBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFvpJF0hOC5yMEC2JO69VS5?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
BL21 (DE3)	MUjGeY5kfGmxbjDhd5NigQ>?		Mo\WNkBpenN?		M3PMcmJqdmSrbnegZYZncW6rdImgeI8hVi22ZYLtbY52eyB6WDDIbZMufGGpZ3XkJIh2dWGwIFLjcE15VCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wNFEh\|ryPLh?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
Toledo	M{m3XmFxd3C2b4Ppd{Bie3OjeR?=				NFS3[5VKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGTvcIVldyClZXzsd{whVER3MDC9JFAvODZizszNMi=>	NFnyZnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY2Oid-MkS5NFA3PTJ:L3G+
KB	MoLHR5l1d3SxeHnjbZR6KGG\|c3H5	NEXqPWsxNjVidV2=			NX7aN2JJS3m2b4TvfIlkcXS7IHnuJIh2dWGwIIPpVm5CNW2nZHnheIVlNU2FTEGtb45kd2tiZH;3ckBMSiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDCR2wzKGG2IECuOUB2VQ>?	NVX2fZFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwOFAxPDNpPkG4NFQxODR\|PD;hQi=>
Eu-Myc	NF60R\|VCeG:ydH;zbZMh[XO\|YYm=	M1PvR\|EhfU1?			NHr6W4JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJI1wfXOnIFX1MW16[yClZXzsd{BwfmW{ZYjwdoV{e2mwZzDCR2wzKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2:ub375JIZwem2jdHnvckBifCBzIIXN	M1jpRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MESwNFQ{Lz5zOEC0NFA1OzxxYU6=
HeLa	M4e4OGZ2dmO2aX;uJIF{e2G7	M1XtOFEhfU1?	NGHINlEyOiCqcoO=		M4W0TGlv\HWldHnvckBw\iCEY3ytfGwudWWmaXH0[YQh[XCxcITvd4l{KGmwIHTvfJlkgWOuaX6td5RqdXWuYYTl[EBpfW2jbjDI[WxiKGOnbHzzJI93\XKneIDy[ZN{cW6pIF7vfIEh[XRiMTD1UUBi\nSncjCxNkBpenNiYomgTI9m[2i\|dDDzeIFqdmmwZx?=	NGXKN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO4Olk5Oid-MkKzPFY6QDJ:L3G+
HeLa	NFTQbWdHfW6ldHnvckBie3OjeR?=	NUXpdGpOOTBidV2=	M3LBVVE3KGi{cx?=		M13EZWlvcGmkaYTpc44hd2ZiUnz1Z{1D[XhxZWnGVE1D[2xveFygbY51\XKjY4Tpc44h\XiycnXzd4VlKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOTZiaILzJIJ6KEKURWSgZZN{[Xl?	MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MkWwN\|EoRjJ{NEK1NFMyRC:jPh?=
MDA-MB-231	NH;NenBHfW6ldHnvckBie3OjeR?=	M2DNb\|AvODNidH:gNUB2VQ>?	MnzkNUBpeg>?		M4fr[GFvfGGpb37pd5Qh[WO2aY\peJkh[XRicnXjc41jcW6jboSgRoNtNViOIHHzd4V{e2WmIHHzJJJme3SxcnH0bY9vKG:oIFLJUUBDUDNvaX7keYNm\CCVbXHjJJBzd3SnaX6gdoVt\WG\|ZTDpckBucXSxY3jvcoRzcWFiaYPvcIF1\WRiZoLvcUBOTEFvTVKtNlMyKGOnbHzzJIF1KDBwMEOgeI8hOSC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NWLLVnJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFc2QThpPkKyO\|Q4PTl6PD;hQi=>
MDA-MB-231	NWnqdXZXTnWwY4Tpc44h[XO\|YYm=	NHXxfFcxNjB\|IITvJFEhfU1?	MnT1NUBpeg>?		NWDNRpoySW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBD[2xvWFygZZN{\XO\|ZXSgZZMhemW\|dH;yZZRqd25ib3[gRmlOKEKKMz3pcoR2[2WmIHP5eI9kcHKxbXWgZ{Bz\WynYYPlJIlvKG2rdH;jbI9v\HKrYTDpd49t[XSnZDDmdo9uKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyBzIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NF\kdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
BP3	MkGwRZBweHSxc3nzJIF{e2G7	MmrUNVAhfU1?	Ml7yNlQhcHK\|		MX;JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEKSMzDj[YxteyCjdDCxNEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBCdm6neHnuJHYh[W6mIIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQhTkGFUzDt[ZRpd2R?	M1;NPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MES3NlI5Lz5{M{C0O\|IzQDxxYU6=
IM9	M4DyT2Fxd3C2b4Ppd{Bie3OjeR?=	MknrNVAhfU1?	MVOyOEBpenN?		MoXDTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCLTUmgZ4VtdHNiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhSW6wZYjpckBXKGGwZDDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKE[DQ2OgcYV1cG:m	M4Dwc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MES3NlI5Lz5{M{C0O\|IzQDxxYU6=
RS4:11	MWLBdI9xfG:\|aYOgZZN{[Xl?	NWrUdlhYOTBidV2=	NVXodnc3OjRiaILz		M2SwdWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUmO0PlEyKGOnbHzzJIF1KDFyIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IFHucoV5cW5iVjDhcoQheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKG2ndHjv[C=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB2N{KyPEc,OjNyNEeyNlg9N2F-
HCT116	MVzBdI9xfG:\|aYOgZZN{[Xl?		M{\X[lQ5KGi{cx?=		MkD4TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ2SxNVYheDV\|Kz:rJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZvRlnUR{B{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNibXX0bI9l	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
DMS53	M3;pNWFxd3C2b4Ppd{Bie3OjeR?=	MmjROUB1dyBzMDD1US=>	MkPyNVIhcHK\|		MknXTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCGTWO1N{Bk\WyuczDoZZJjd3KrbnegdFU{KG23dHHueEBie3Onc4Pl[EBieyCleYTvZ4hzd22nIHOgdoVt\WG\|ZTDheEA2KHSxIEGwJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
DMS53	NYHE[HRrTnWwY4Tpc44h[XO\|YYm=	NWSxeZltPSC2bzCxNEB2VQ>?	MWCxNkBpenN?		NET3UWlKdmirYnn0bY9vKG:oIFLDcE0zN0KrbTDpcpRmemGldHnvckBqdiCqdX3hckBFVVN3MzDj[YxteyCqYYLic5JqdmdicEWzJI12fGGwdDDheEA2KHSxIEGwJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;wdoVkcXCrdHH0bY9vKG2ndHjv[C=>	M3eyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUiyN\|czLz5{Nkm4NlM4OjxxYU6=
DMS53	NXnUTI5RSXCxcITvd4l{KGG\|c3H5	NXTHOnE3PSC2bzCxNEB2VQ>?	MYixNkBpenN?		M3LY[Glv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iRF3TOVMh[2WubIOgbIFz[m:{aX7nJJA2OyCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCB3IITvJFExKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	NVewS4ZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	NUPHUIpXSXCxcITvd4l{KGG\|c3H5	M4LJblUhfG9iMUCgeW0>	NEHufFIyOiCqcoO=		NFfycXRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFTNV\|U{KGOnbHzzJIhiemKxcnnu[{BxPTNibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2VvMzDjcIVifmGpZTDheEA2KHSxIEGwJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	NXTPdWZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	NV3zcodKTnWwY4Tpc44h[XO\|YYm=	M{HLTFUhfG9iMUCgeW0>	M4XTdlEzKGi{cx?=		NYPnfndHUW6qaXLpeIlwdiCxZjDCR4wuOi:EYYigbY51\XKjY4Tpc44hcW5iaIXtZY4hTE2VNUOgZ4VtdHNiaHHyZo9zcW6pIIC1N{BufXSjboSgZZQhPSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vdJJm[2myaYTheIlwdiCvZYToc4Q>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
U-2 OS	M1XzU5FJXFNiYYPzZZk>				NF;OU5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	M1zXVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MkTzdWhVWyCjc4PhfS=>				NWLUcJlJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NITzTpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	M1P5ZpFJXFNiYYPzZZk>				M{G3ZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MVLxTHRUKGG\|c3H5				M3rMbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NYjYbVVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NHf0eXZyUFSVIHHzd4F6				MoKwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NFzwfGpyUFSVIHHzd4F6				M{fTWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NY\VN29QeUiWUzDhd5NigQ>?				Ml7MdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	M{\GT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NUPqd2Z5eUiWUzDhd5NigQ>?				NFX5SXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NF23O2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M1j5TpFJXFNiYYPzZZk>				MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	M4rMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NGj4eFRyUFSVIHHzd4F6				MkPWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsdy=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MX7xTHRUKGG\|c3H5				MmLMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	NES3UZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NVnQU\|ZUeUiWUzDhd5NigQ>?				NXLZ[HU3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	NF3qWnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	Mo\adWhVWyCjc4PhfS=>				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	MmHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NH7mbG9yUFSVIHHzd4F6				NEDwNFByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	NIO1XmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MWPxTHRUKGG\|c3H5				NHOwcmVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NVO0dJNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MmTodWhVWyCjc4PhfS=>				NFf6eXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	NUTGeIRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MVrxTHRUKGG\|c3H5				NV3wUHF2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NHLyS5pyUFSVIHHzd4F6				NGrYN4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NYrQSm5QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NV;XeItOeUiWUzDhd5NigQ>?				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	M123TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M4XTV5FJXFNiYYPzZZk>				M3HsNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	M17EPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NXu3Rok6eUiWUzDhd5NigQ>?				MlvwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NHP4WoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MUnxTHRUKGG\|c3H5				MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NWT2VG5wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MlfsdWhVWyCjc4PhfS=>				NVjRVHp3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	M{PMdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MYjxTHRUKGG\|c3H5				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	NXvzNIdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NIDZN\|hyUFSVIHHzd4F6				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	M1fDdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NGPsUG1yUFSVIHHzd4F6				Mo\ldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	NGjLNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NX\zTnRyeUiWUzDhd5NigQ>?				NFrq[mJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	NUe1WGxCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

体内研究

ABT-737按30 mg/kg剂量作用于白血病模型，抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。^[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。^[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。^[5]

激酶实验： ^[1]	- 合并荧光偏振实验: 测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后，加入20 nM FITC-BIM BH3 肽。进行荧光偏振，测定IC50值。
细胞实验： ^[4]	- 合并 Cell lines: SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114 Concentrations: 0.001-10 μM Incubation Time: 48小时 Method: SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时，使用MTS测定存活细胞。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 注射ER细胞的Scid 鼠 Dosages: 20 mg/kg和30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2%DMSO+40%PEG300+5%Tween80+53%ddH2O	2mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download ABT-737 SDF

分子量	813.43
化学式	C₄₂H₄₅ClN₆O₅S₂
CAS号	852808-04-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the recommended method about reconstitution of the compound for in vivo animal study?
回答：
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
活性最高的Bcl-2抑制剂

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

研究领域

产品类型

定制您的化合物库

ABT-737

客户使用Selleck生产的ABT-737发表文献322篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download ABT-737 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品